Company Filing History:
Years Active: 2022
Title: Lawrence Dearth: Innovator in Biopharmaceutical Antibodies
Introduction: Lawrence Dearth, an inventive mind based in Encinitas, CA, has made significant strides in the field of biopharmaceuticals. With one notable patent to his name, he contributes to the development of antibodies that exhibit low immunogenicity, enhancing therapeutic potential in human applications.
Latest Patents: Dearth’s patent, titled "Antibodies with low immunogenicity and uses thereof," highlights a groundbreaking approach to antibody engineering. This patent provides detailed insights into antibodies and their antigen-binding fragments that demonstrate minimal to no immunogenicity in humans. The patent also presents compositions containing these antibodies and outlines methods for their production and application in various medical treatments, paving the way for safer biopharmaceutical products.
Career Highlights: Lawrence Dearth is associated with Celgene Corporation, a company renowned for its innovation in biopharmaceuticals. His work there focuses on advancing therapeutic options that minimize immune reactions, which is critical in drug development and patient safety.
Collaborations: Throughout his career, Dearth has collaborated with esteemed professionals in the field, including Jeffrey C. Johnson and Haralambos Hadjivassiliou. These collaborations facilitate a robust exchange of ideas and techniques, further enhancing the scope of research and development in antibody technology.
Conclusion: Lawrence Dearth exemplifies the spirit of innovation in the biopharmaceutical realm, particularly through his patent focused on low immunogenicity antibodies. His contributions at Celgene Corporation, along with collaborations with other experts, underline the importance of teamwork in advancing healthcare solutions.